FigureĀ 1.
Categorical heatmap showing the patient demographics, status of SF gene mutation, relevant myeloid mutations, treatment intensity, exposure to venetoclax, ORR, and frequency of SCT. (A) SFmut group. (B) SFwt group. ELN AR, ELN 2017 AR; SCT, allogeneic SCT; VEN, venetoclax.